APA (7th ed.) Citation

I, G., H, Y., F, M., G, M., N, T., V, M., . . . S, C. (2022). Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature medicine, 28(5), 1097. https://doi.org/10.1038/s41591-022-01827-x

Chicago Style (17th ed.) Citation

I, Ganan-Gomez, et al. "Author Correction: Stem Cell Architecture Drives Myelodysplastic Syndrome Progression and Predicts Response to Venetoclax-based Therapy." Nature Medicine 28, no. 5 (2022): 1097. https://doi.org/10.1038/s41591-022-01827-x.

MLA (9th ed.) Citation

I, Ganan-Gomez, et al. "Author Correction: Stem Cell Architecture Drives Myelodysplastic Syndrome Progression and Predicts Response to Venetoclax-based Therapy." Nature Medicine, vol. 28, no. 5, 2022, p. 1097, https://doi.org/10.1038/s41591-022-01827-x.